News
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results